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Introduction
Maggot therapy, the use of sterile maggots to clear and cleanse 
necrotic wounds, was flourishing in the 1930s and early 1940s, being 
widely used in hospitals in the USA and Canada. Then, one day in 
London, a young Scottish scientist, Alexander Fleming, accidently 
discovered penicillin growing in his petri dishes, and by the mid-40s, 
the industrial antibiotic era had commenced in earnest. This marvel 
saw an end to maggot therapy, albeit only temporarily, while everybody 
excitedly began using antibiotics for everything. Overuse of antibiotics 
has now resulted in the emergence of several species of bacteria resistant 
to almost any antibiotic therapy. Seventy years later, we can no longer 
rely on antibiotics to treat necrotic tissue wound infections. Meanwhile, 
diseases, such as obesity and diabetes, previously unknown in past 
populations, are escalating alarmingly. Resulting from these conditions, 
we see a huge rise in patients with non-healing and chronic wounds, 
coupled with the perturbing presence of resistant microbes. As such, 
maggot therapy is being re-visited as an alternative to antibiotic therapy 
for infected tissues and is gaining renewed interest and advocacy for 
debridement and ultimate healing of necrotic tissues too.
Wounds and Myiasis
Maggot therapy is essentially an artificially induced myiasis. Trained 
clinicians apply sterile larvae of the green bottle fly (Lucilia sericata), 
onto a wound in serious need of debridement and often disinfection. 
The larvae feast on dead necrotic tissue, eliminate infection and appear 
to promote healthy tissue formation. After about 4 days, the larvae are 
removed and the wound re-assessed for further therapy. Whilst the 
culture of disgust and disdain that surrounds the application of maggots 
onto one’s own body may exist, there appears nonetheless to have been 
a general worldwide increase in the clinical use of maggots to manage 
wounds. This revival, in part, is due to the numerous published reports 
of successful clinical outcomes following larval treatment. In addition, 
the last decade has seen significant technological advances that have 
aided our understanding of the scientific principles and physiological 
pathways which underlie the action of maggots in wounds, and, it is 
argued, that the efficiency of medicinal maggots is now beyond doubt.
Maggots appear to be able to combat wounds in three ways: 
debridement, disinfection and the acceleration of healing. The 
advances in our understanding of clinical myiasis and its treatment, 
therefore, stem from both clinical reports and the results of laboratory 
investigations, in these three arenas.
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Advances in medicinal maggot-led wound debridement 
This facet of maggot action is the best understood of all. It has been 
firmly established that maggots produce a combination of proteolytic 
and other digestive enzymes which are released externally in their 
secretions, and which get distributed over the wound as the maggot 
crawls around. Two key enzymes, trypsin and chymotrypsin, have been 
identified and studies indicate that the success of maggot enzymatic 
debridement is mastered through the ability of these enzymes to 
withstand endogenous wound inhibitors, which would normally 
degrade and destroy other, perhaps autolytic, enzymes [1]. Recently, 
larval chymotrypsin was shown to effectively degrade macromolecules 
present in venous leg ulcer slough, molecules such as fibrin and 
fibrinogen [2]. These constituents often act as key substrate sites for 
notorious wound bacterial biofilm to attach and accumulate. So, 
maggot debriding enzymes may play more than one role and indirectly 
and advertently help in the control or elimination of more troublesome 
wound microbial challenges.  
Despite an increasing abundance of successful reports of maggot 
therapy from clinical case studies, controlled and retrospective studies, 
the faith in maggots as expedient wound debriders was also put to the 
test in the last few years through the gold standard for comparative 
scientific rigor – the Randomised Controlled Trial (RCT). In all RCTs 
undertaken and published to date however, maggot therapy has been 
proven to be a much more effective debriding tool that its control 
counterparts [3].
Advances in wound disinfection by medicinal maggots
Researchers have long been convinced that larval secretions contain 
effective antibacterial agents.  In recent years, more and more evidence 
has gathered to confirm the presence of discrete antibacterial moieties 
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within larval secretions. Modern and advanced scientific technologies 
have further unlocked our understanding of these secreted factors, 
and have shed new light on their nature. For example, a large (high 
molecular weight) peptide, Lucifensin, has been purified from larval 
secretions and various larval tissues [4]. Lucifensin has been shown to 
be potently active against several bacteria including S. pyogenes and S. 
pneumoniae. Additionally, a small antibacterial molecule, Seraticin®, 
has been isolated in fractions collected from sterile larval secretions, 
with powerful activity against 12 out of 15 tested clinical isolates of 
MRSA, as well as a range of other pathogens. A further investigation on 
antimicrobial activities of compounds released externally by L. sericata 
has confirmed the presence of a range of structurally diverse compounds, 
and most recently, research scientists in China have reported the 
isolation and purification of yet another antibacterial molecule from 
larval secretions [5]. This protein, MAMP, has a significant inhibitory 
effect on S. aureus and appears to work by disrupting the bacterial cell 
membrane [6]. In addition, another group of researchers have posited 
that over 45 antimicrobial peptides including lucifensin, lucimycin, 
attacins, cecropins, diptericins, proline-rich peptides, and sarcotoxins, 
are coded in L. sericata. Some of these peptides possess a broad 
spectrum activity against microbial pathogens, including Pseudomonas 
aeruginosa, Proteus vulgaris, and Enterococcus faecalis, suggesting that 
there may be a repertoire of available antibacterial agents at the disposal 
of the medicinal maggot.
The inducible nature of larval antibacterial activity had been 
reported previously, but has also been verified yet again more recently, 
with results indicating that that infected larvae have much better 
antibacterial capacities than sterile larvae [7]. Researchers argue 
that the clinical wound situation would enable larvae in the infected 
environment to influence production of their antibacterial activities. 
This discovery suggests that sterile larvae placed in an infected wound, 
are triggered by the presence, or by oral ingestion, of surrounding 
bacteria, and commence production and secretion of their antibacterial 
agents, acting like small, antibiotic-secreting factories, and indeed, 
this has led some researchers to hypothesise that microbe stimulated 
maggots could become the next targeted natural antibiotic family [8].
In terms of the microbial burden of a wound, it is generally agreed 
that wound chronicity is aggravated by the presence of a biofilm. Wound 
biofilm is extremely difficult to eradicate; many topical treatments are 
ineffective, and many antibiotics, designed to attack free (planktonic) 
bacterial cells cannot penetrate this walled community. It has been 
shown that larval secretions can not only disrupt established biofilm, 
but can also prevent its formation. Furthermore, it was recently shown 
that chymotrypsin derived from larval secretions was the molecule 
responsible for the disruption of protein-dependent bacterial biofilm 
formation [9]. This detrimental effect on biofilm was observed for both 
nascent and pre-formed biofilms of Staphylococcus epidermidis 5179-R1.
In addition, larval secretions reportedly contain an enzyme, a 
DNAse, which is able to break down DNA from wound slough and 
is also able to digest bacterial DNA [10]. This discovery is significant 
since extracellular DNA is an important requirement for some bacterial 
species to instigate biofilm formation. If DNAse present in larval 
secretions eliminates all sources of extracellular DNA, then this may 
explain the observed anti-biofilm effects of larvae and their secretions. 
Interestingly, like the antibacterial molecules previously mentioned, 
larval molecules associated with disruption of biofilm have also been 
shown to be inducible, for example, secretions collected from larvae 
incubated with bacteria were able to better destroy P. aeruginosa biofilm 
[11] Other studies have considered the effects of larvae on biofilm 
production upon surfaces commonly used in a medical setting, and 
a recent study found that larval secretions were able to both prevent 
biofilm formation, and disrupt existing biofilms of P. aeruginosa [12]. 
The study, which encompassed many different bacterial species, noted 
reduced biofilm formations after treatment with larval secretions on 
polyethylene, titanium and stainless steel surfaces, with a maximal 
reduction in biofilm formation of 92%. This result may be of great 
significance, especially when considering peri-prosthetic infections. 
It remains to be seen if anti-biofilm components from maggot 
secretions can be exploited by the disciplines of nanotechnology 
and bioengineering, and utilised to produce prostheses capable of 
combatting such infections.  
It has also been newly revealed that L. sericata is capable of 
producing and externalising antifungal components, and of particular 
note, is the secretion of a small molecule (< 500 Da), anti-Candida 
factor [13]. It seems highly probable therefore, that in a wound, larvae 
secrete distinct factors which are able to combat wound pathogens, as 
well as interfering with bacterial biofilm formation and establishment.
Acceleration of wound healing by medicinal maggots
Of all the advances in myiasis treatment, the understanding 
behind the action of maggot therapy and its role in acceleration of 
new tissue growth is possibly the most exciting.  While progress in our 
pre-clinical and scientific knowledge gathers momentum, it has to be 
said that recent RCTs which have assessed wound closure and healing, 
have not found any significant difference between larval therapy 
and other therapies. Nonetheless, numerous clinical studies have 
been performed which show that the application of maggot therapy 
exhibited a significantly shorter time to granulation, and to overall 
healing of lesions. For example, Marineau et al. [14] examined complex 
diabetic foot wounds in a set of 23 patients and found that 74% of them 
showed enhanced granulation tissue formation. The presence of poorly 
perfused tissue in the impairment of wound healing has always been 
a clinical obstacle. An interesting report was recently published by a 
team of Japanese surgeons, who measured an increase in skin perfusion 
pressure surrounding a post-amputation chronic wound, after MT on 
a patient with critical limb ischemia. Following MT, skin perfusion 
pressure increased dramatically, from 12 to 54 mmHg on the dorsal 
aspect of the foot, and from 17 to 44 mmHg on the plantar aspect. 
The authors surmised that somehow the presence of maggots on the 
wound had contributed to the increase in blood supply to the ischaemic 
wound, providing more clinical evidence that healing may be actively 
accelerated following a dose of maggots [15].
Not to be outdone by such fascinating clinical findings, laboratory 
science too has investigated the effects of maggot secretions on key cells 
and molecules known to be pivotal to wound healing. Such investigations 
have led to discoveries which begin to reveal the actual processes and 
molecular mechanisms that may play a part a role in wound healing. For 
example, several studies suggest that the beneficial effects of maggots may 
lie in their ability to reduce levels of pro-inflammatory factors thereby 
inhibiting on-going inflammation. Yet other researchers have shown 
that maggot secretions are capable of breaking down key components of 
the Complement Cascade, a system of potent serum enzymes which can 
trigger an inflammatory response [16].
Central to wound healing is the migration of essential cells such as 
dermal cells, fibroblasts and microvascular cells into the wound bed. 
Recently, Wang et al. [17], showed a significant increase in the migration 
of human microvascular epidermal cells following exposure to maggot 
secretions. Using wound healing assays to examine the possibility that 
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there may be distinct pathways activated, the investigators found that 
the migration was indeed due to the activation of a key signalling protein 
AKT1, which normally regulates cell migration during wound healing.
Fibroblasts are the fundamental cells responsible for the production 
of collagen and ECM, and therefore healthy granulation tissue. Maggot 
secretions have previously been reported to enhance fibroplasia, and, 
recently, other researchers have added evidence to support enhanced 
fibroblast proliferation. Polakovicova et al. [18] showed that when 
fibroblasts were cultured with extracts from maggot salivary glands, the 
cells responded with an increased metabolism and protein production, 
and the formation of microfibrillar nets, structures which are requisite 
for fibroblast cell migration.
Additionally, many researchers have shown that maggot secretions 
and larval therapy can up-regulate the production of growth factors, 
the body’s own protein molecules which have a huge role in the wound 
healing process, helping with the stimulation and proliferation of 
new tissue. Honda et al. [19] recently reported that blood samples 
from patients treated with maggots showed a remarkable increase in 
endogenous HGF, after just a single application. The authors credited 
the increased levels of HGF to the promotion of healthy granulation 
tissue. In pre-clinical investigations, it was found that in the presence 
of maggot secretions, macrophages significantly increased their 
production of pro-angiogenic βFGF and VEGF [20], and other work, 
too, supports the notion of maggot secretions promoting angiogenesis. 
The amino acids L-histidine, 3-guanidinopropionic acid (GPA) and 
L-valinol were identified in maggot secretions, and it was demonstrated 
that these isolated components specifically enhanced the proliferation of 
human vascular endothelial cells, whilst having no effect on fibroblasts, 
with the amino acid valinol eliciting the greatest increase in endothelial 
cell proliferation [21].  
So, in conclusion, it appears that in maggot therapy may have some 
beneficial and practical aspects. Maggots are able to digest necrotic 
debris from an unhealthy wound, disinfect and cleanse at source, and 
most likely promote the formation and development of new healthy 
tissue. These advances in our understanding have been possible because 
of the tireless efforts of both clinicians and laboratory scientists, which 
have provided us with a much better apprehension of the wound healing 
potential of medicinal maggot therapy.
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